Clinical trial · Interventional
Irinotecan and Anlotinib for Epithelioid Sarcoma
A Retrospective Study Investigating the Combination of Irinotecan, Vincristine and Anlotinib for Epithelioid Sarcoma
NCT05656222CI-TRIAL-00063992withdrawnN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Check the IRB again
Summary
Brief summary (as posted)
Epithelioid sarcoma is a rare soft tissue sarcoma characterized by SMARCB1/INI1 deficiency. Much attention has been paid to the selective EZH2 inhibitor tazemetostat, where other systemic treatments are generally ignored. To explore alternative treatment options, we studied the effects of irinotecan-based chemotherapy in a series of epithelioid sarcoma patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Objective Response | — | UNRESOLVED | — |
| Overall Survival | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| VIA combination treatment | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- VIA treatment Group
- interventionNames
- Drug: VIA combination treatment
Primary outcomes (1)
- measure
- Objective Response Rate
- timeFrame
- 12 weeks
- description
- Based on RECIST1.1 criteria, clinical evaluation was done once every 6 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 3 Years
Show eligibility criteria text
Inclusion Criteria: * (1) Grade 2 or 3 ES confirmed histologically using the American Joint Committee on Cancer (AJCC) system ; * (2) patients presented with measurable lesions using the Response Evaluation Criteria In Solid Tumors (RECIST1.1) and were not amenable to surgical resection or radiotherapy; * (3) primary or secondary metastatic disease; * (4) received more than two courses of the VIA regimen; * (5) no concurrent treatment was given while on the VIA regimen; * (6) follow-up information and evaluation after chemotherapy were available. Exclusion Criteria: * less than 4 cycles of treatment; * medical records were not complete.
References
Publications (1)
- DERIVEDXie L, Sun X, Xu J, Liang X, Liu K, Sun K, Yang R, Tang X, Guo W. The efficacy and safety of vincristine, irinotecan and anlotinib in Epithelioid Sarcoma. BMC Cancer. 2024 Feb 3;24(1):172. doi: 10.1186/s12885-024-11921-7. PMID 38310286